BGLC (BioNexus Gene Lab) Total Liabilities : $1.61 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is BioNexus Gene Lab Total Liabilities?

BioNexus Gene Lab's Total Liabilities for the quarter that ended in Sep. 2024 was $1.61 Mil.

BioNexus Gene Lab's quarterly Total Liabilities declined from Mar. 2024 ($1.82 Mil) to Jun. 2024 ($1.59 Mil) but then increased from Jun. 2024 ($1.59 Mil) to Sep. 2024 ($1.61 Mil).

BioNexus Gene Lab's annual Total Liabilities declined from Dec. 2021 ($2.40 Mil) to Dec. 2022 ($2.08 Mil) and declined from Dec. 2022 ($2.08 Mil) to Dec. 2023 ($1.74 Mil).

BioNexus Gene Lab Total Liabilities Historical Data

The historical data trend for BioNexus Gene Lab's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNexus Gene Lab Total Liabilities Chart

BioNexus Gene Lab Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

0.11

3.45

2.40

2.08

1.74

BioNexus Gene Lab Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															1.78	1.74	1.82	1.59	1.61

BioNexus Gene Lab Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BioNexus Gene Lab's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.631	+	(0.099	+	-1.7347234759768E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0.012	+	0	+	0)
	=	1.74

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	11.4	-	9.658
	=	1.74

BioNexus Gene Lab's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.415	+	(0.178	+	-4.336808689942E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0.014	+	0	+	0)
	=	1.61

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	10.995	-	9.388
	=	1.61

BioNexus Gene Lab Total Liabilities Related Terms

Thank you for viewing the detailed overview of BioNexus Gene Lab's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNexus Gene Lab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BGLC:USA

Address

No. 8 Jalan Kerinchi, The Vertical Business Suite II, Unit 02, Level 10, Tower B, Avenue 3, Bangar South, Kuala Lumpur, SGR, MYS, 59200

Website

https://www.bionexusgenelab.com

BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

Executives

Chak Hua Yew	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yeat Min Fong	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Teng Fook Fong	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chee Keong Yap	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Boon Teong Teoh	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Yee Meng Wong	director, officer: President	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Wei Li Leong	officer: Chief Financial Officer	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chai Ping Lin	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Tai Tan Liong	director, officer: Chief Operating Officer	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Sook Keng Yeoh	director, officer: Chief Executive Officer	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200